

Zilver® PTX™ Drug-Eluting Stent Trial

The Zilver PTX Drug-Eluting Stent Trial is taking place in centers around the world to determine whether a stent coated with paclitaxel is successful in treating blockages above the knee in the femoropopliteal artery (the major artery in the thigh) and helping prevent the arteries from narrowing over time.

Following are some questions to discuss with your doctor:

- 1 Has my peripheral arterial disease progressed to a point where lifestyle changes and drug therapy are no longer effective?
- 2 Are the symptoms of my peripheral arterial disease classified as Rutherford Category 2 or greater, meaning the symptoms are moderate to severe?
- 3 Am I willing to participate in a clinical study and adhere to a thorough and regular follow-up schedule?
- 4 Have I received any treatment with a stent in the past for my PAD?
- 5 Is my peripheral arterial disease in the superficial femoral artery, or in the artery above the knee?

The Zilver PTX Drug-Eluting Stent Trial is being conducted at 31 sites in the United States as well as sites in Asia, Canada, Latin America and Europe. To find more information about the trial or to locate a clinical site close to you log on to www.zilverptx.com.